Guidelines of Polish Myeloma Group concerning diagnosis and therapy of multiple myeloma and other plasmacytic dyscrasias for 2013

Abstract

New drugs introduced in recent years to the therapy of multiple myeloma (MM) patients allow to obtain therapeutic responses in the majority of patients. Therapeutic regimens based on thalidomide, lenalidomide and on bortezomib are recommended to the therapy as well of patients being candidates to high dose therapy and autologous stem cell transplantation as unfit to such procedure. In relapsed/refractory patients regimens based on the same dugs in combinations of 2, 3 or 4 drugs are utilized. Integral part of MM therapy is maintenance therapy and supportive care. In this article we described also therapeutic recommendation for Waldenström macroglobulinemia and other plasmocytic dyscrasias.